Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective
Aim: The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-01-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1827905882717945856 |
|---|---|
| author | Brian Murray Jennifer Miles-Thomas Amy J Park Victor B Nguyen Amy Tung Patrick Gillard Anjana Lalla Victor W Nitti Christopher J Chermansky |
| author_facet | Brian Murray Jennifer Miles-Thomas Amy J Park Victor B Nguyen Amy Tung Patrick Gillard Anjana Lalla Victor W Nitti Christopher J Chermansky |
| author_sort | Brian Murray |
| collection | DOAJ |
| description | Aim: The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists,
onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two
including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were
compared with best supportive care (BSC) using a previously published Markov model. Materials &
methods: Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were
performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were
derived from published sources. Results: UsingMedicare and commercial costs over a 15-year time period,
onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/qualityadjusted
life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all
assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA
to be the most cost-effective of all assessed treatments versus BSC. Conclusion: OnabotulinumtoxinA
100U is currently the most cost-effective treatment for OAB. |
| first_indexed | 2024-03-13T00:48:12Z |
| format | Article |
| id | doaj.art-31dbbad2d057467385654cb7d75607fb |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-13T00:48:12Z |
| publishDate | 2023-01-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-31dbbad2d057467385654cb7d75607fb2023-07-08T12:26:01ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132023-01-0112210.2217/cer-2022-0089Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspectiveBrian Murray0Jennifer Miles-Thomas1Amy J Park2Victor B Nguyen3Amy Tung4Patrick Gillard5Anjana Lalla6Victor W Nitti7Christopher J Chermansky8Capital Region Urological Surgeons, 319 S Manning Blvd #106, Albany, NY 12208, USAEastern Virginia Medical School, 225 Clearfield Ave, Virginia Beach, VA 23462, USACleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USACurta, Inc., 4872 Beach Dr SW, Seattle, WA 98116, USAAllergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USAAllergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USAAllergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USADavid Geffen School of Medicine at UCLA, 300 Stein Plaza Driveway, Los Angeles, CA 90095, USAUniversity of Pittsburgh Medical Center Magee Womens Hospital, 300 Halket St, Suite 2541, Pittsburgh, PA 15213, USAAim: The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Materials & methods: Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources. Results: UsingMedicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/qualityadjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC. Conclusion: OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.anticholinergicβ3-adrenoceptor agonistcost–effectivenessmarkov modelonabotulinumtoxinaoveractive bladderquality-adjusted life-yearrechargeable sacral nerve stimulation |
| spellingShingle | Brian Murray Jennifer Miles-Thomas Amy J Park Victor B Nguyen Amy Tung Patrick Gillard Anjana Lalla Victor W Nitti Christopher J Chermansky Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective Journal of Comparative Effectiveness Research anticholinergic β3-adrenoceptor agonist cost–effectiveness markov model onabotulinumtoxina overactive bladder quality-adjusted life-year rechargeable sacral nerve stimulation |
| title | Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective |
| title_full | Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective |
| title_fullStr | Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective |
| title_full_unstemmed | Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective |
| title_short | Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective |
| title_sort | cost effectiveness of overactive bladder treatments from a us commercial and payer perspective |
| topic | anticholinergic β3-adrenoceptor agonist cost–effectiveness markov model onabotulinumtoxina overactive bladder quality-adjusted life-year rechargeable sacral nerve stimulation |
| work_keys_str_mv | AT brianmurray costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT jennifermilesthomas costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT amyjpark costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT victorbnguyen costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT amytung costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT patrickgillard costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT anjanalalla costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT victorwnitti costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective AT christopherjchermansky costeffectivenessofoveractivebladdertreatmentsfromauscommercialandpayerperspective |